Article
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
The Lancet. Oncology - 1 Sept 2011
Gelmon Karen A, Tischkowitz Marc, Mackay Helen, Swenerton Kenneth, Robidoux André, Tonkin Katia, Hirte Hal, Huntsman David, Clemons Mark, Gilks Blake, Yerushalmi Rinat, Macpherson Euan, Carmichael James, Oza Amit
Abstract excerpt
BACKGROUND: Olaparib (AZD2281) is a small-molecule, potent oral poly(ADP-ribose) polymerase (PARP) inhibitor. We aimed to assess the safety and tolerability of this drug in patients without BRCA1 or BRCA2 mutations with advanced triple-negative breast cancer or high-grade serous and/or undifferentiated ovarian cancer. METHODS: In this phase 2, multicentre, open-label, non-randomised study, women with advanced...
Topics
Join the communities discussing this publication.